N
NPCE
Neuropace Inc
12.67
-0.55-4.16%After Hours: 12.67 0.00 0.00%17:19 10/06 EDT
OPEN/PREV CLOSE13.38/13.22
TODAY RANGE12.66-13.38
VOL82.99K
MARKET CAP434.89M
52 WEEK RANGE9.22-19.60
AVG VOL (3M)170.62K
% TURNOVER0.20%
TURNOVER--
P/E (TTM)-22.3299
% RANGE5.45%
EPS(TTM)-0.5674
P/E(FORWARD)-24.6825
P/B36.56
BVPS0.3466
DIVIDEND--
P/S4.255
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP340.21M
SHARES OUTSTANDING34.32M
NEXT EARNINGS11/02-11/06
FREE FLOAT26.85M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·09/18 11:53
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Dow Jones·09/18 10:47
NeuroPace Price Target Announced at $18.00/Share by Keybanc
TipRanks·09/18 09:15
NeuroPace initiated with an Overweight at KeyBanc
NASDAQ·09/10 15:30
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
TipRanks·08/26 00:23
Neuropace Earnings Call Shows Strong Growth Amid FDA Risk
NASDAQ·08/17 17:17
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NASDAQ·08/17 17:06
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NASDAQ·08/17 16:59
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
TipRanks·08/17 12:36
NeuroPace (NPCE) Receives a Buy from Cantor Fitzgerald
NASDAQ·08/12 15:22
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
TipRanks·08/12 10:57
Wells Fargo Gives a Buy Rating to NeuroPace (NPCE)
NASDAQ·08/11 21:25
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
Same Industry
Name/Symbol
Change%
Price